To assess the utility of STAT3 inhibitors in recurrent patient tumors, a likely clinical scenario where individuals may be prescribed novel agents, and when PMT characterizes aggressive recurrence, we evaluated TCGA glioma-intrinsic subtypes (GISs) with STAT3 status as defined by the STAT3 gene signature4. Here, STAT3 is linked to glioma.